ClinicalTrials.Veeva

Menu

KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)

AstraZeneca logo

AstraZeneca

Status

Completed

Conditions

Non-Small Cell Lung Cancer

Study type

Observational

Funder types

Industry

Identifiers

NCT02777567
D5160R00009

Details and patient eligibility

About

The objectives of this study are to assess the safety and efficacy of single agent Tagrisso (Osimertinib, hereinafter "the study drug") in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), Who Have Progressed on or after EGFR tyrosine kinase receptor (TKI) therapy.

Enrollment

315 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

    1. Eligible for, or on active study drug treatment according to the approved label; patients with locally advanced or metastatic, EGFR T790M mutation-positive NSCLC, who have progressed on or after EGFR tyrosine kinase receptor (TKI) therapy
    1. Provision of signed and dated written informed consent by the patient or legally acceptable representative

Exclusion criteria

    1. History of hypersensitivity to excipients of the study drug or to drugs with a similar chemical structure or class to the study drug
    1. Pregnancy and/or breast feeding
    1. Current participation in any interventional trial

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems